INTRODUCTION
Embryonic stem cells (ESCs), which can theoretically differentiate into any cell type, have become a key cellular tool in biology and have paved the way for cell-based treatments of human diseases 1 . However, human ES cells (hESCs) have two major drawbacks. The [ ] first one is the ethical issue concerning the destruction of human embryos to generate hESCs, although these embryos were doomed to destruction anyway 2 . The second barrier to their potential medical use is the need of Human Leukocyte Antigen (HLA)-compatible [ ] hESC lines. Both issues are circumvented by induced pluripotent stem cells (iPSCs) as they are directly reprogrammed from adult cells 3 , [ ] thus opening the way to the derivation of patient-specific pluripotent stem cell (PCS) lines 4 . Moreover, by carefully selecting donor [ ] cells, for instance from donors who are homozygous for HLA, it will be possible to set up PSC banks that cover a large part of the genetic diversity of a population 5 . As iPSC derivation allows the production of cells from potentially any tissue in an unlimited supply [ ] in vitro and from any genetic background, many applications can therefore be foreseen, particularly: (i) modeling of human development, in vitro
(ii) modeling of human genetic diseases, (iii) supply of normal or diseased cells for drug testing, (iv) supply of cells for cell in vitro therapies, including patient-specific cells, and (v) rejuvenation of old/senescent cells for regenerative medicine 6 . In addition, the iPS [ ] technology can be mastered with a reasonable amount of training and costs and is now successfully used in many laboratories worldwide (for a discussion on the iPS technology and its applications we refer the readers to other recent reviews 3,7 ). However, several reports are [ ] raising concerns about the potential weaknesses of iPSCs, such as the appearance of genetic or epigenetic abnormalities linked to the process of cell reprogramming. By altering the iPSC biological behavior or threatening their therapeutic safety, these defects could undermine their use for modeling diseases and medical applications. This problem might tip the balance back towards ESCs. In this review, we will focus on the genetic alterations observed in iPSCs and ESCs and discuss the fact that cell reprogramming is only one of the possible sources of genetic variation in PSCs.
TRACKING THE GENETIC DAMAGE PRODUCED BY CELL REPROGRAMMING
The generation of iPS by cell reprogramming opens the way to two potential sources of mutations. First, insertional mutagenesis due to the use of integrative vectors for cell reprogramming is an obvious cause of DNA damage (Figure 1 ). In the initial reports, Southern blot analyses showed that each iPSC clone was characterized by the presence of more than 20 integration events (about half a dozen integration events for each transcription factor) 8 . Although aberrant transcription of an oncogene following the integration of a retroviral vector in [ ] its proximity has been already described in gene therapy trials 9 , similar examples of insertional mutagenesis with functional [ ] consequences on endogenous genes are not a typical finding in iPSCs. Nonetheless, the definitive insertion of reprogramming vectors in the iPSC genome is a serious concern and the reactivation of the c-MYC transgene might have fatal consequences, as illustrated by the development of tumors in germline-competent adult chimeras, which were obtained using iPSCs generated with retroviral vectors, and in their progeny 10 . Safer reprogramming strategies have been developed and are now available, such as the use of non-integrating viral [ ] vectors, or the direct delivery of reprogramming transcription factor proteins or synthetic mRNAs (discussed below). [ -] 12.9 and hESCs, suggesting that cell reprogramming is not a significant source of karyotype abnormality. On the other hand, there were % differences concerning the occurrence of some abnormalities, such as higher incidence of trisomy 12 in hESCs and of trisomy 8 in iPCs, and most strikingly almost 10 of trisomy 17 in hESCs, but none in iPSCs. Interestingly, in this very large data set, recurrent % translocations were not found, differently from what is observed in many cancers. This is, however, a retrospective analysis and it is not clear whether the observed differences relate to the methods used to generate these PSC lines or whether they only reflect biases in the in cell expansion protocols. vitro
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NOT ALL iPS CELLS HARBOR GENETIC DAMAGE
The idea that subkaryotypic abnormalities are unavoidable during cell reprogramming was also recently questioned. Qinlan et al. used whole-genome paired-end DNA sequencing to compare three iPSC lines that were generated by reprogramming mouse embryonic fibroblasts (MEF) with four lentiviral constructs coding for OCT4, SOX2, CMYC and KLF4 under the control of a doxycycline inducible promoter 29 . These low-passage iPSC lines were previously used to generate viable mice in tetraploid embryo complementation assays, [ ] undisputedly demonstrating that complete reprogramming had occurred. Unexpectedly, the authors found only one or two de novo structural genomic variations in each iPSC line. As a matter of fact, the most important source of genomic alteration was the de novo insertion of endogenous retroviral elements from the mouse leukemia virus (MLV) family that most likely originated from the CF-1 MEFs which were used as feeder cells. In another study, Young et al. analyzed by whole genome sequencing iPSC clones that were obtained using an OCT4, SOX2 and KLF4 polycistronic lentiviral vector and their parental fibroblasts. Their findings suggest that the single-nucleotide variations and the rare structural variations (SV) detected in the iPSC lines reflected the parental genomic background rather than the consequences of reprogramming 30 . These findings have been extended in human iPSC generated by using the canonical captures pre-existing mutations in the parental cell line during cloning, which is a necessary consequence of reprogramming. These data " obtained by whole genome sequencing of mouse iPSC lines were extended to human iPSC lines that were obtained using non-integrating Epstein-Barr nuclear antigen-1 (oriP/EBNA1) episomal vectors. Although more than 1,000 single nucleotide variations (SNVs) were found in each iPSC line, very few were within coding sequences 32 . Among those, 50 were synonymous changes, whereas SNVs that
modify the coding sequence were not enriched for known cancer-associated genes. Moreover, no CNV was found in the analyzed iPSC lines.
Overall, the studies suggesting that cell reprogramming may be inherently linked to DNA damage are counterbalanced by other works
showing that the mutation status of iPSC lines is similar to that of their parental cells. Nevertheless the reports about the occurrence of genome alterations during cell reprogramming are alarming as they highlight DNA damage. These contradictory reports could be bona fide explained mainly by two reasons: (1) [ ] whether the source cell type, the nature of the reprogramming vector (for instance with viral integration versus without integration) or the choice of the reprogramming gene combination, are correlated with the incidence of genomic abnormalities. In one report, some of these factors could be evaluated but none of these factors influenced the results 20 , but these results are too preliminary to reach any [ ] conclusion.
CELL CULTURE-INDUCED GENOMIC ALTERATIONS
It will not be possible to precisely quantify the genetic abnormalities generated by cell reprogramming without knowing the role played by the cell culture conditions in the mutational process. Indeed, a cell culture protocol that favors the appearance of DNA alterations in PSCs will also do so during cell reprogramming and during the first passages which are required to amplify newly derived human iPSCs. In this regard, much can be learned from ESCs. ESCs are karyotypically normal at derivation 33,34 and the occurrence of sub-karyotypic abnormalities even faster when using single-cell dissociation passaging (unpublished data). These findings in ESCs indicate that the culture conditions used for cell reprogramming and cell expansion are a critical factor for DNA integrity during iPSC generation. Moreover, as several studies on genomic alterations in iPSCs were based on DNA samples isolated from cells before passage 20, it is not possible to exclude a contribution of the cell culture conditions to the DNA abnormalities that were ascribed to cell reprogramming 22 . Many issues need to be addressed to prevent these deleterious mutational events, particularly: (1) to identify the [ ] optimal culture conditions for PSC expansion and (2) to understand the mechanisms that drive the generation of genomic alterations.
Therefore, a quantitative assay is required to measure the genomic integrity of PSCs in order to compare the impact of different parameters on the incidence of mutational events.
IMPROVING CELL REPROGRAMMING
Overall, the genome integrity of human iPSCs and ESCs is comparable, although some differences have been reported. We will focus here on the measures that can be taken to diminish DNA damage during cell reprogramming.
To avoid insertional mutagenesis, several non-integrating approaches are currently available (see 3 for a discussion on these [ ]
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The other concern is reprogramming-induced DNA damage. As its causes are still not clearly understood, the solution of this type of damage is still speculative. One direction could be to improve the reprograming transcription factor cocktail. Combinations that may improve cell reprogramming could associate the classical reprogramming factors with genes coding for components of the ATP-dependent information, but also because of the cell/tissue DNA information heterogeneity. DNA modifications arise continuously from early embryo development to adulthood and their occurrence increases during aging, leading to various degree of cell mosaicism 59 61 . The causes of [ -] these lesions are multiple and include, but are not limited to, random events promoted notably by reactive oxygen species (ROS), retrotransposition, UV (for skin fibroblasts) or senescence. Cell mosaicism can be readily observed in primary fibroblasts used for cell reprogramming when these cells are analyzed by using high-throughput techniques 22, 31 . As this genetic heterogeneity is uncovered by [ ] whole genome sequencing, there is an acute need to set up a demarcation line between acceptable and off-limit DNA alterations in the primary parental cells as well as in the freshly reprogrammed PSCs and long-term cultured PSCs. To this aim, the lesions that alter the cellular physiology or that pose a risk of malignant transformation must be identified 19 . As there is no means to assess the functionality Mutations that target a coding region and that are predicted to alter the protein sequence by giving rise to a new stop codon, a frameshift or a new splicing event.
Genetic defects that occur recurrently in cultured PSCs. To this aim, the creation of a PSC sequence database should be a key objective of scientists working on human PSCs. These recurrent mutations could be driving mutations (as opposed to passenger
mutations) that confer a growth advantage to the cells. In addition, integration of these data with metabolic and phenotypic information will be instrumental for hierarchizing the abnormalities. Validation of these recurrent genetic abnormalities on large series of samples by independent techniques, for instance by digital droplet PCR for CNV, will be necessary 31 . In addition, measuring the impact of these abnormalities on the expression of the genes present in the vicinity by expression analysis will help in determining their functional consequences on the biology of PSC.
High-resolution, whole-genome sequencing data are ideally needed for the implementation of these guidelines, but they are not routinely available at the moment due to the actual costs of sequencing and the still complex pipeline analysis of such massive amount of data. Meanwhile, karyotyping will still be the reference test together with FISH analysis of chromosome 12, 17 and 20, and/or low-resolution CGH to exclude gross karyotype abnormalities.
CONCLUSION
The genetic integrity of iPSCs has been questioned and invoked as an argument against their medical use. However, these results have been challenged by reports that described the generation of iPSCs with low incidence of DNA sequence variations. Two factors may be central to PSC genetic stability: (i) the culture conditions, which can rapidly affect PSC genomic stability and (ii) the reprogramming protocols. As specific culture conditions are associated with very different rates of genetic variations, it can be anticipated that different starting cell types, reprogramming transcription factors and vectors, reprogramming protocols and early culture/passaging conditions can specifically affect the type/load of genomic damage linked to cell reprogramming. We therefore call for a careful quantification of the impact on genome integrity of all these factors in order to optimize the reprogramming protocols and ultimately provide safe iPSCs, both for research and clinical applications.
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